Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML [clinicaltrials:NCT00568633]

Bio2RDF uri

Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML [clinicaltrials:NCT00568633]

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

http://bio2rdf.org/clinicaltrials:NCT00568633

Bio2RDF identifier

NCT00568633

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00568633

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT00568633

anticipated enrollment [clinicaltrials_vocabulary:anticipated-enrollment]

150

http://www.w3.org/2001/XMLSchema#integer

arm group [clinicaltrials_vocabulary:arm-group]

NCT00568633 arm group f8a344fc1b40632ddd988a6522172181 [clinicaltrials_resource:NCT00568633/arm-group/f8a344fc1b40632ddd988a6522172181]

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:ca1954f55de6b13c270f49787460e895

brief summary [clinicaltrials_vocabulary:brief-summary]

Acute myeloid leukemia ...... of older AML patients.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Overall survival defined as the date of documented complete remission (CR) until the dte of the latest follow-up or death by any cause 2 years [clinicaltrials_resource:2241820f1fce649aa822e35dad02138b]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Overall survival defined as the date of documented complete remission (CR) until the dte of the latest follow-up or death by any cause 2 years [clinicaltrials_resource:1fd1e930dc391327f445fc05c8421567]

Overall survival defined as the date of documented complete remission (CR) until the dte of the latest follow-up or death by any cause 2 years [clinicaltrials_resource:4aa742c3114e99c73580af288f265723]

Overall survival defined as the date of documented complete remission (CR) until the dte of the latest follow-up or death by any cause 2 years [clinicaltrials_resource:4de0c103c78aacfbddaadd196e1bb538]

Overall survival defined as the date of documented complete remission (CR) until the dte of the latest follow-up or death by any cause 2 years [clinicaltrials_resource:8650ad72a242fff5f77b55e280e21602]

Overall survival defined as the date of documented complete remission (CR) until the dte of the latest follow-up or death by any cause 2 years [clinicaltrials_resource:a4914cde84571563a3ab5a0b623ae05d]

collaborator [clinicaltrials_vocabulary:collaborator]

Stanford University [clinicaltrials_resource:269fc60adb004b0b719031a97aedf5e9]

completion date [clinicaltrials_vocabulary:completion-date]

2017-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00568633 [clinicaltrials_resource:b1d2baf4d49a94f052b53d128b666c48]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2007-12-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

Anti-Thymocyte Globulin [clinicaltrials_resource:018de343c7b5e73b2fdeaa7da25cdeac]

Hematopoietic Cell Transplantation [clinicaltrials_resource:4115d8bd37537ee37fa34ce9bb716056]

Cellcept [clinicaltrials_resource:52227feabccb0f6213fba8dbb41fd3df]

Cyclosporine [clinicaltrials_resource:9a2ff88e9440980ca4d12ca87f4197ce]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Mycophenolate mofetil [clinicaltrials_resource:31de209b7264303fdda3c8b57bf0b039]

Antilymphocyte Serum [clinicaltrials_resource:49f1b34e227936be908f6e1129577ee9]

Cyclosporins [clinicaltrials_resource:a78396bd0ab3d3f25852a0d4008cbdf4]

Cyclosporine [clinicaltrials_resource:d5ad0819e34429f7e4abc786a3f5366c]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2013-11-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Stanford University [clinicaltrials_resource:269fc60adb004b0b719031a97aedf5e9]

location [clinicaltrials_vocabulary:location]

Kaiser Permanente Northern California [clinicaltrials_resource:b3596cd4810ad51a3e1aa97a464ffee9]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00568633

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

A California Cooperative Clini ...... L) in First Complete Remission

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

BMT190

http://www.w3.org/2001/XMLSchema#string

overall official [clinicaltrials_vocabulary:overall-official]

Louis Fehrenbacher [clinicaltrials_resource:065fc1bb9283a3b530fe5f0350638fab]

overall status [clinicaltrials_vocabulary:overall-status]

Terminated [clinicaltrials_resource:fba9c4daa2dd29d1077d32d965320ac1]

oversight [clinicaltrials_vocabulary:oversight]

United States: Institutional Review Board [clinicaltrials_resource:b5a2933cbbd357d5860e15ecc488e5c1]

phase [clinicaltrials_vocabulary:phase]

Phase 3 [clinicaltrials_resource:8357418e2694434468870b487644532d]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2017-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:dbd41868ee618d3e64daa1adf8c3a8a0]

secondary id [clinicaltrials_vocabulary:secondary-id]

97,843

http://www.w3.org/2001/XMLSchema#integer

source [clinicaltrials_vocabulary:source]

Stanford University [clinicaltrials_resource:269fc60adb004b0b719031a97aedf5e9]

start date [clinicaltrials_vocabulary:start-date]

2007-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00568633 study design [clinicaltrials_resource:48c29924e5dee1e7af979f049c3764c8]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00568633

verification date [clinicaltrials_vocabulary:verification-date]

2013-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

why stopped [clinicaltrials_vocabulary:why-stopped]

Poor accrual

http://www.w3.org/2001/XMLSchema#string

identifier

clinicaltrials:NCT00568633

http://www.w3.org/2001/XMLSchema#string

title

Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

Allogeneic HCT Using Nonmyeloa ...... L [clinicaltrials:NCT00568633]

@en